Omnicell (NASDAQ:OMCL)‘s stock had its “buy” rating reiterated by stock analysts at Oppenheimer in a research report issued to clients and investors on Tuesday. They currently have a $55.00 price objective on the stock. Oppenheimer’s price objective points to a potential upside of 7.84% from the company’s previous close.
A number of other research firms have also weighed in on OMCL. Zacks Investment Research lowered shares of Omnicell from a “hold” rating to a “strong sell” rating in a research note on Wednesday, November 1st. Craig Hallum reaffirmed a “buy” rating and issued a $62.00 price objective (up from $52.00) on shares of Omnicell in a research note on Monday, October 30th. Cantor Fitzgerald raised their price objective on shares of Omnicell to $58.00 and gave the company an “overweight” rating in a research note on Friday, October 27th. Finally, Benchmark raised their price objective on shares of Omnicell from $55.00 to $67.00 and gave the company a “buy” rating in a research note on Tuesday, September 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $55.14.
Omnicell (OMCL) traded down $1.15 during trading on Tuesday, hitting $51.00. 229,600 shares of the company’s stock were exchanged, compared to its average volume of 256,245. Omnicell has a 12-month low of $31.85 and a 12-month high of $55.40. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.08 and a current ratio of 1.53.
In other news, VP Peter J. Kuipers sold 3,532 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $50.96, for a total value of $179,990.72. Following the completion of the sale, the vice president now owns 40,714 shares in the company, valued at $2,074,785.44. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Robin Gene Seim sold 9,780 shares of the stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $48.97, for a total transaction of $478,926.60. Following the completion of the sale, the executive vice president now owns 55,896 shares of the company’s stock, valued at approximately $2,737,227.12. The disclosure for this sale can be found here. In the last quarter, insiders sold 38,944 shares of company stock valued at $1,889,592. 3.77% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of OMCL. Turner Investments LLC purchased a new stake in Omnicell during the second quarter worth about $181,000. Flinton Capital Management LLC increased its holdings in Omnicell by 74.6% during the second quarter. Flinton Capital Management LLC now owns 4,216 shares of the company’s stock worth $182,000 after buying an additional 1,802 shares during the last quarter. Riverhead Capital Management LLC increased its holdings in Omnicell by 76.3% during the second quarter. Riverhead Capital Management LLC now owns 4,230 shares of the company’s stock worth $182,000 after buying an additional 1,830 shares during the last quarter. Sei Investments Co. increased its holdings in Omnicell by 36.4% during the second quarter. Sei Investments Co. now owns 4,652 shares of the company’s stock worth $200,000 after buying an additional 1,242 shares during the last quarter. Finally, Pinebridge Investments L.P. increased its holdings in Omnicell by 1.6% during the second quarter. Pinebridge Investments L.P. now owns 4,896 shares of the company’s stock worth $211,000 after buying an additional 76 shares during the last quarter. Institutional investors and hedge funds own 99.84% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Oppenheimer Reaffirms “Buy” Rating for Omnicell (OMCL)” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://stocknewstimes.com/2017/12/06/oppenheimer-reaffirms-buy-rating-for-omnicell-omcl.html.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.